Loading clinical trials...

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy

NCT06359847•Beijing Scitech-Mq Pharmaceuticals Limited

View on ClinicalTrials.gov

Summary

ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc. The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy. All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Eligibility Minimum Age: 18 Years
•Maximum Age:
•Sex: All
•Gender Based:
•Accepts Healthy Volunteers: No
•1. Age \>= 18 years
•2. Life expectancy of twelve weeks or more
•3. Histologically or cytologically confirmed locally advanced or metastatic DTC that cannot be removed by surgery or radiotherapy, including papillary thyroid cancer, follicular thyroid cancer, hurthle cell thyroid cancer or poorly differentiated thyroid cancer.
•4. At least one measurable lesion according to RECIST 1.1
•5. Radioiodine-refractory (RAI-refractory) differentiated thyroid cancer can be diagnosed when any of the following criteria are met under thyroid-stimulating hormone (TSH) stimulation (\>30 mU/L) in the absence of exogenous iodine interference:
+16 more criteria

Exclusion Criteria

•1. Other histological subtypes of thyroid cancers excluding DTC (such as Anaplastic Thyroid Carcinoma and Medullary Thyroid Carcinoma).
•2. Known hypersensitivity to any component of ST-1898 tablets.
•3. Participants who have received any antitumor treatment within 4 weeks or 5 half-lives of the agent (contingent on the shorter time) prior to the first dose of study drug.
•4. Patients who underwent major surgery, open biopsy or significant traumatic injury within 4 weeks prior to the first dose of study drug.
•5. Serious non-healing wound/ulcer/bone fracture.
•6. ≥ grade 3 bleeding episodes within 6 months prior to first dose of study treatment, or currently ≥ grade 2 hemorrhage, with high bleeding risks (such as coagulation disorders, tracheobronchial infiltration with significant bleeding, active gastrointestinal ulcer and esophageal varices)
•7. Active hemoptysis or more than 0.5 teaspoon (2.5 mL) of hemoptysis per day within 2 months before first dose of study treatment
•8. Subjects with antiplatelet agents treatment (low-dose aspirin ≤100 mg/day is permitted).
•9. Current or previous severe retinopathy who, in the judgment of the Investigator or specialist, are not suitable for enrollment
•10. Significant cardiovascular impairment, including but not limited to:
+19 more criteria

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

November 15, 2023

Primary Completion Date

December 1, 2027

Completion Date

December 1, 2027

Last Updated

August 24, 2025

Enrollment

ESTIMATED participants

Conditions

Differentiated Thyroid Carcinoma

Interventions

ST-1898 tablets

DRUG

Contacts

Yansong Lin, MD

CONTACT

0086-10-69151188 linyansong1968@163.com

Xin Zhang, MD

CONTACT

0086-10-69151188 zhangxin37@pumch.cn

[177Lu]Lu-AKIR001 First-in-human Study

NCT06639191

Thyroid Gland Anaplastic CarcinomaPoorly Differentiated Thyroid Carcinoma+4 more

View study

ACTIVE_NOT_RECRUITINGNA

The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer

NCT06422702

Pathologically Confirmed Differentiated Thyroid CarcinomaAll Patients Are in the Initial Treatment Phase+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Inclusion Criteria

Exclusion Criteria

[177Lu]Lu-AKIR001 First-in-human Study

The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer

Post-Marketing Surveillance of Lenvima in Korean Patients

The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma